25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ABCL (Abcellera) Stock Analysis
Buy, Hold or Sell?

Let's analyze Abcellera together

I guess you are interested in Abcellera Biologics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Abcellera’s Financial Insights
  • 📈 Technical Analysis (TA) – Abcellera’s Price Targets

I'm going to help you getting a better view of Abcellera Biologics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Abcellera Biologics Inc

I send you an email if I find something interesting about Abcellera Biologics Inc.

1. Quick Overview

1.1. Quick analysis of Abcellera (30 sec.)










1.2. What can you expect buying and holding a share of Abcellera? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.37
Expected worth in 1 year
$3.02
How sure are you?
34.6%

+ What do you gain per year?

Total Gains per Share
$-0.35
Return On Investment
-7.3%

For what price can you sell your share?

Current Price per Share
$4.77
Expected price per share
$3.83 - $5.26
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Abcellera (5 min.)




Live pricePrice per Share (EOD)
$4.77
Intrinsic Value Per Share
$-48.92 - $-58.70
Total Value Per Share
$-45.55 - $-55.33

2.2. Growth of Abcellera (5 min.)




Is Abcellera growing?

Current yearPrevious yearGrowGrow %
How rich?$1b$1.1b-$102.9m-9.9%

How much money is Abcellera making?

Current yearPrevious yearGrowGrow %
Making money-$41.4m-$38.3m-$3m-7.5%
Net Profit Margin-685.8%-464.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Abcellera (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#61 / 853

Most Revenue
#301 / 853

Most Profit
#738 / 853

Most Efficient
#617 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Abcellera?

Welcome investor! Abcellera's management wants to use your money to grow the business. In return you get a share of Abcellera.

First you should know what it really means to hold a share of Abcellera. And how you can make/lose money.

Speculation

The Price per Share of Abcellera is $4.77. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Abcellera.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Abcellera, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.37. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Abcellera.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.12-2.4%-0.14-2.9%-0.13-2.7%-0.11-2.3%0.000.0%0.000.0%
Usd Book Value Change Per Share-0.05-1.1%-0.09-1.8%-0.07-1.5%-0.06-1.2%0.153.2%0.132.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.05-1.1%-0.09-1.8%-0.07-1.5%-0.06-1.2%0.153.2%0.132.7%
Usd Price Per Share3.43-2.80-4.45-5.25-10.70-8.23-
Price to Earnings Ratio-7.38--5.31--8.85--6.89--45.23--34.79-
Price-to-Total Gains Ratio-64.44--37.00--69.30--61.94--43.77--43.77-
Price to Book Ratio1.02-0.80-1.16-1.36-3.28-2.52-
Price-to-Total Gains Ratio-64.44--37.00--69.30--61.94--43.77--43.77-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.77
Number of shares209
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.090.15
Usd Total Gains Per Share-0.090.15
Gains per Quarter (209 shares)-18.1732.04
Gains per Year (209 shares)-72.66128.15
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-73-830128118
20-145-1560256246
30-218-2290384374
40-291-3020513502
50-363-3750641630
60-436-4480769758
70-509-5210897886
80-581-594010251014
90-654-667011531142
100-727-740012821270

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%5.015.00.025.0%7.019.00.026.9%7.019.00.026.9%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%7.013.00.035.0%9.013.04.034.6%9.013.04.034.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.026.00.0%0.00.026.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%7.013.00.035.0%9.013.04.034.6%9.013.04.034.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Abcellera Biologics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.053-0.087+63%-0.070+32%-0.057+8%0.153-135%0.130-141%
Book Value Per Share--3.3703.484-3%3.828-12%3.778-11%3.451-2%2.669+26%
Current Ratio--11.07310.091+10%8.598+29%9.301+19%9.120+21%7.364+50%
Debt To Asset Ratio--0.2820.243+16%0.221+27%0.222+27%0.221+28%0.229+23%
Debt To Equity Ratio--0.3920.322+22%0.284+38%0.287+37%0.288+36%0.348+13%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--1183090162.5601108906045.120+7%1733536064.400-32%1986188962.803-40%3905462746.361-70%3905462746.361-70%
Eps---0.116-0.139+19%-0.128+10%-0.110-5%0.002-5012%0.001-7927%
Ev To Ebitda Ratio---7.617-6.953-9%-8.447+11%-22.135+191%-30.705+303%-30.705+303%
Ev To Sales Ratio--17.31343.783-60%53.341-68%46.299-63%51.507-66%51.507-66%
Free Cash Flow Per Share---0.153-0.116-24%-0.142-7%-0.137-11%0.001-21210%0.002-6376%
Free Cash Flow To Equity Per Share---0.164-0.108-34%-0.129-22%-0.130-21%0.097-270%0.088-287%
Gross Profit Margin--1.0871.076+1%1.0890%1.071+1%1.104-2%0.848+28%
Intrinsic Value_10Y_max---58.701----------
Intrinsic Value_10Y_min---48.917----------
Intrinsic Value_1Y_max---1.321----------
Intrinsic Value_1Y_min---1.295----------
Intrinsic Value_3Y_max---7.446----------
Intrinsic Value_3Y_min---7.039----------
Intrinsic Value_5Y_max---17.762----------
Intrinsic Value_5Y_min---16.187----------
Market Cap1425433371.840+28%1024997162.560835985295.120+23%1329806814.400-23%1585201046.136-35%3292158209.043-69%2532429391.572-60%
Net Profit Margin---2.033-6.858+237%-4.649+129%-4.457+119%-2.789+37%-2.168+7%
Operating Margin---2.686-9.146+240%-8.435+214%-6.742+151%-4.138+54%-3.217+20%
Operating Ratio--4.31615.237-72%9.777-56%10.013-57%6.692-36%5.495-21%
Pb Ratio1.415+28%1.0180.805+26%1.159-12%1.359-25%3.279-69%2.522-60%
Pe Ratio-10.262-39%-7.379-5.308-28%-8.845+20%-6.888-7%-45.227+513%-34.790+371%
Price Per Share4.770+28%3.4302.798+23%4.450-23%5.251-35%10.698-68%8.229-58%
Price To Free Cash Flow Ratio-7.786-39%-5.599-6.617+18%-9.632+72%-8.761+56%-723.568+12824%-556.590+9841%
Price To Total Gains Ratio-89.616-39%-64.441-36.997-43%-69.298+8%-61.944-4%-43.768-32%-43.768-32%
Quick Ratio--17.41315.975+9%14.068+24%14.664+19%14.241+22%14.265+22%
Return On Assets---0.025-0.030+22%-0.026+5%-0.023-8%0.003-1014%-0.002-90%
Return On Equity---0.034-0.040+15%-0.034-3%-0.030-14%0.002-1601%-0.011-67%
Total Gains Per Share---0.053-0.087+63%-0.070+32%-0.057+8%0.153-135%0.130-141%
Usd Book Value--1007076000.0001041059000.000-3%1143993500.000-12%1135582166.667-11%1043551402.450-3%807016340.192+25%
Usd Book Value Change Per Share---0.053-0.087+63%-0.070+32%-0.057+8%0.153-135%0.130-141%
Usd Book Value Per Share--3.3703.484-3%3.828-12%3.778-11%3.451-2%2.669+26%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--1183090162.5601108906045.120+7%1733536064.400-32%1986188962.803-40%3905462746.361-70%3905462746.361-70%
Usd Eps---0.116-0.139+19%-0.128+10%-0.110-5%0.002-5012%0.001-7927%
Usd Free Cash Flow---45769000.000-34746750.000-24%-42535658.000-7%-41515969.333-9%372368.400-12391%848892.115-5492%
Usd Free Cash Flow Per Share---0.153-0.116-24%-0.142-7%-0.137-11%0.001-21210%0.002-6376%
Usd Free Cash Flow To Equity Per Share---0.164-0.108-34%-0.129-22%-0.130-21%0.097-270%0.088-287%
Usd Market Cap1425433371.840+28%1024997162.560835985295.120+23%1329806814.400-23%1585201046.136-35%3292158209.043-69%2532429391.572-60%
Usd Price Per Share4.770+28%3.4302.798+23%4.450-23%5.251-35%10.698-68%8.229-58%
Usd Profit---34727000.000-41416250.000+19%-38325000.000+10%-32739333.333-6%1834427.100-1993%1503378.692-2410%
Usd Revenue--17084000.0008219000.000+108%8263750.000+107%17592250.000-3%58304913.600-71%45907492.885-63%
Usd Total Gains Per Share---0.053-0.087+63%-0.070+32%-0.057+8%0.153-135%0.130-141%
 EOD+5 -3MRQTTM+22 -16YOY+18 -203Y+14 -245Y+8 -3010Y+12 -26

3.3 Fundamental Score

Let's check the fundamental score of Abcellera Biologics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-10.262
Price to Book Ratio (EOD)Between0-11.415
Net Profit Margin (MRQ)Greater than0-2.033
Operating Margin (MRQ)Greater than0-2.686
Quick Ratio (MRQ)Greater than117.413
Current Ratio (MRQ)Greater than111.073
Debt to Asset Ratio (MRQ)Less than10.282
Debt to Equity Ratio (MRQ)Less than10.392
Return on Equity (MRQ)Greater than0.15-0.034
Return on Assets (MRQ)Greater than0.05-0.025
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Abcellera Biologics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.046
Ma 20Greater thanMa 504.295
Ma 50Greater thanMa 1004.388
Ma 100Greater thanMa 2003.525
OpenGreater thanClose4.360
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Abcellera Biologics Inc

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Fundamental data was last updated by Penke on 2025-08-23 09:09:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Abcellera earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • A Net Profit Margin of -203.3% means that $-2.03 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Abcellera Biologics Inc:

  • The MRQ is -203.3%. The company is making a huge loss. -2
  • The TTM is -685.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-203.3%TTM-685.8%+482.6%
TTM-685.8%YOY-464.9%-221.0%
TTM-685.8%5Y-278.9%-407.0%
5Y-278.9%10Y-216.8%-62.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-203.3%-85.5%-117.8%
TTM-685.8%-171.0%-514.8%
YOY-464.9%-210.0%-254.9%
3Y-445.7%-289.9%-155.8%
5Y-278.9%-381.1%+102.2%
10Y-216.8%-520.3%+303.5%
4.3.1.2. Return on Assets

Shows how efficient Abcellera is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • -2.5% Return on Assets means that Abcellera generated $-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Abcellera Biologics Inc:

  • The MRQ is -2.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.5%TTM-3.0%+0.5%
TTM-3.0%YOY-2.6%-0.4%
TTM-3.0%5Y0.3%-3.3%
5Y0.3%10Y-0.2%+0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.5%-11.9%+9.4%
TTM-3.0%-11.9%+8.9%
YOY-2.6%-11.2%+8.6%
3Y-2.3%-12.0%+9.7%
5Y0.3%-11.7%+12.0%
10Y-0.2%-13.8%+13.6%
4.3.1.3. Return on Equity

Shows how efficient Abcellera is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • -3.4% Return on Equity means Abcellera generated $-0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Abcellera Biologics Inc:

  • The MRQ is -3.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.4%TTM-4.0%+0.5%
TTM-4.0%YOY-3.4%-0.6%
TTM-4.0%5Y0.2%-4.2%
5Y0.2%10Y-1.1%+1.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.4%-14.2%+10.8%
TTM-4.0%-15.2%+11.2%
YOY-3.4%-15.3%+11.9%
3Y-3.0%-16.9%+13.9%
5Y0.2%-17.5%+17.7%
10Y-1.1%-19.6%+18.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Abcellera Biologics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Abcellera is operating .

  • Measures how much profit Abcellera makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • An Operating Margin of -268.6% means the company generated $-2.69  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Abcellera Biologics Inc:

  • The MRQ is -268.6%. The company is operating very inefficient. -2
  • The TTM is -914.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-268.6%TTM-914.6%+646.0%
TTM-914.6%YOY-843.5%-71.1%
TTM-914.6%5Y-413.8%-500.8%
5Y-413.8%10Y-321.7%-92.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-268.6%-154.1%-114.5%
TTM-914.6%-280.2%-634.4%
YOY-843.5%-268.7%-574.8%
3Y-674.2%-281.5%-392.7%
5Y-413.8%-350.8%-63.0%
10Y-321.7%-530.7%+209.0%
4.3.2.2. Operating Ratio

Measures how efficient Abcellera is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 4.32 means that the operating costs are $4.32 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 4.316. The company is inefficient in keeping operating costs low. -1
  • The TTM is 15.237. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.316TTM15.237-10.921
TTM15.237YOY9.777+5.459
TTM15.2375Y6.692+8.545
5Y6.69210Y5.495+1.197
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.3161.952+2.364
TTM15.2372.974+12.263
YOY9.7773.047+6.730
3Y10.0133.835+6.178
5Y6.6924.924+1.768
10Y5.4956.864-1.369
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Abcellera Biologics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Abcellera is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 11.07 means the company has $11.07 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 11.073. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.091. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ11.073TTM10.091+0.982
TTM10.091YOY8.598+1.493
TTM10.0915Y9.120+0.971
5Y9.12010Y7.364+1.756
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.0733.480+7.593
TTM10.0913.790+6.301
YOY8.5984.104+4.494
3Y9.3014.609+4.692
5Y9.1205.764+3.356
10Y7.3646.154+1.210
4.4.3.2. Quick Ratio

Measures if Abcellera is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • A Quick Ratio of 17.41 means the company can pay off $17.41 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 17.413. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 15.975. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ17.413TTM15.975+1.439
TTM15.975YOY14.068+1.907
TTM15.9755Y14.241+1.733
5Y14.24110Y14.265-0.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.4132.938+14.475
TTM15.9753.291+12.684
YOY14.0683.928+10.140
3Y14.6644.393+10.271
5Y14.2415.837+8.404
10Y14.2656.549+7.716
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Abcellera Biologics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Abcellera assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Abcellera to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.28 means that Abcellera assets are financed with 28.2% credit (debt) and the remaining percentage (100% - 28.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 0.282. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.243. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.282TTM0.243+0.039
TTM0.243YOY0.221+0.021
TTM0.2435Y0.221+0.022
5Y0.22110Y0.229-0.008
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2820.339-0.057
TTM0.2430.359-0.116
YOY0.2210.334-0.113
3Y0.2220.341-0.119
5Y0.2210.349-0.128
10Y0.2290.379-0.150
4.5.4.2. Debt to Equity Ratio

Measures if Abcellera is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • A Debt to Equity ratio of 39.2% means that company has $0.39 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 0.392. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.322. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.392TTM0.322+0.071
TTM0.322YOY0.284+0.038
TTM0.3225Y0.288+0.033
5Y0.28810Y0.348-0.060
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3920.391+0.001
TTM0.3220.436-0.114
YOY0.2840.436-0.152
3Y0.2870.461-0.174
5Y0.2880.461-0.173
10Y0.3480.514-0.166
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Abcellera generates.

  • Above 15 is considered overpriced but always compare Abcellera to the Biotechnology industry mean.
  • A PE ratio of -7.38 means the investor is paying $-7.38 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Abcellera Biologics Inc:

  • The EOD is -10.262. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.379. Based on the earnings, the company is expensive. -2
  • The TTM is -5.308. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.262MRQ-7.379-2.883
MRQ-7.379TTM-5.308-2.071
TTM-5.308YOY-8.845+3.538
TTM-5.3085Y-45.227+39.920
5Y-45.22710Y-34.790-10.437
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.262-2.539-7.723
MRQ-7.379-2.361-5.018
TTM-5.308-2.657-2.651
YOY-8.845-3.749-5.096
3Y-6.888-3.883-3.005
5Y-45.227-6.353-38.874
10Y-34.790-7.102-27.688
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Abcellera Biologics Inc:

  • The EOD is -7.786. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.599. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.617. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.786MRQ-5.599-2.187
MRQ-5.599TTM-6.617+1.018
TTM-6.617YOY-9.632+3.015
TTM-6.6175Y-723.568+716.951
5Y-723.56810Y-556.590-166.977
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.786-3.411-4.375
MRQ-5.599-2.951-2.648
TTM-6.617-3.614-3.003
YOY-9.632-4.421-5.211
3Y-8.761-5.258-3.503
5Y-723.568-8.587-714.981
10Y-556.590-9.639-546.951
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Abcellera is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.02 means the investor is paying $1.02 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Abcellera Biologics Inc:

  • The EOD is 1.415. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.018. Based on the equity, the company is underpriced. +1
  • The TTM is 0.805. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.415MRQ1.018+0.398
MRQ1.018TTM0.805+0.213
TTM0.805YOY1.159-0.355
TTM0.8055Y3.279-2.474
5Y3.27910Y2.522+0.757
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4152.206-0.791
MRQ1.0182.027-1.009
TTM0.8052.194-1.389
YOY1.1592.425-1.266
3Y1.3592.571-1.212
5Y3.2793.805-0.526
10Y2.5224.462-1.940
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Abcellera Biologics Inc.

4.8.1. Institutions holding Abcellera Biologics Inc

Institutions are holding 38.517% of the shares of Abcellera Biologics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Baker Bros Advisors LP9.21660.67932752564000
2025-03-31ING Investment Management LLC7.11470.02642124837010624185100
2025-06-30Capital World Investors4.47380.00671336109600
2025-06-30Baillie Gifford & Co Limited.3.46890.026510360004-835828-7.4655
2025-06-30UBS Asset Mgmt Americas Inc2.83660.00598471619-7199444-45.941
2025-03-31UBS Group AG1.70170.002150821833106835157.2804
2025-03-31Orbimed Advisors, LLC1.39990.2223418076800
2025-06-30ArrowMark Colorado Holdings, LLC (ArrowMark Partners)1.37450.2536410509500
2025-03-31BlackRock Inc1.19740.00023576208-520435-12.7039
2025-03-31Two Sigma Investments LLC1.0470.01493126789-130522-4.007
2025-03-31Renaissance Technologies Corp0.9690.0098289402940713616.3713
2025-03-31Prosight Management, LP0.94282.06312815652-4534348-61.6918
2025-03-31Two Sigma Advisers, LLC0.88560.01332644800364001.3955
2025-03-31TANG CAPITAL MANAGEMENT LLC0.87060.32082600000171840.6653
2025-03-31Citadel Advisors Llc0.60760.000818144741217223203.8043
2025-03-31Guardian Partners Inc.0.59820.4671178641400
2025-03-31Morgan Stanley - Brokerage Accounts0.43230.0002129101635363137.7253
2025-03-31Novo A/S0.37730.1912112691500
2025-03-31Federated Hermes Inc0.31730.0046947751315143.4395
2025-03-31Millennium Management LLC0.29120.001869709-613006-41.3435
Total 40.1234.3098119828532+1960525+1.6%

4.9.2. Funds holding Abcellera Biologics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30American Funds SMALLCAP World A4.47380.05851336109600
2025-03-25SMDS Global AI Equity Mother1.50360.2819449052000
2025-06-30Baillie Gifford Positive Change1.34960.58424030699-320461-7.365
2025-06-30Baillie Gifford Positive Change B Acc1.34450.58344015467-284713-6.621
2025-06-30UBS Lux Dgtl Hlth Eq Fd seeding P acc1.16361.6417347520000
2025-06-30Baillie Gifford WW Pstv Chg B USD Acc0.77960.60832328331-107663-4.4197
2025-07-31iShares Biotechnology ETF0.46240.11351381000118020.862
2025-06-30ACATIS Datini Valueflex Fonds A0.33480.3909100000000
2024-11-18Nissay Glbl Digital Hlthcare Eq MF0.32232.570896250013950016.9502
2025-07-31iShares Genomics Immnlgy & Hlthcr ETF0.19242.341457453200
2025-07-31SPDR® Portfolio Developed Wld ex-US ETF0.16080.00848024500
2025-06-30Lazard Digital Health0.1592.0824474785-302249-38.8978
2025-02-28Keystone Positive Change Investment Ord0.13520.496240392300
2025-06-30Vanguard Baillie GiffordGlbPstvImpStkInv0.13440.6046401306-28138-6.5522
2025-07-31Desjardins Sustainable Positive Change F0.12730.776438011100
2025-06-30BlackRock Advantage Small Cap Core Instl0.1170.029234941200
2025-07-31SEB Artificial Intelligence D (USD)0.11390.523334026700
2025-07-31iShares Healthcare Innov ETF USD Acc0.0880.128126292700
2025-07-31Fidelity Nasdaq Composite ETF0.07720.012423049100
2025-07-31iShares Nasdaq US Biotech ETF USD Acc0.06020.144817969400
Total 13.099613.9839122506-891922-2.3%

5.3. Insider Transactions

Insiders are holding 22.942% of the shares of Abcellera Biologics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-05-26Andrew BoothBUY145006.85
2023-05-26Holdings Ltd. ThermopylaeBUY1530006.52
2022-12-16Holdings Ltd. ThermopylaeBUY8510210.1
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-06-302024-09-302024-12-312025-03-312025-06-30
Net Debt  -76,25821,017-55,241-35,720-90,961-458-91,419141,06249,643
Gross Profit  -30,714-1,074-31,78822,937-8,851-29,410-38,26155,34517,084



5.2. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets1,402,061
Total Liabilities394,985
Total Stockholder Equity1,007,076
 As reported
Total Liabilities 394,985
Total Stockholder Equity+ 1,007,076
Total Assets = 1,402,061

Assets

Total Assets1,402,061
Total Current Assets742,145
Long-term Assets659,916
Total Current Assets
Cash And Cash Equivalents 92,437
Short-term Investments 460,641
Net Receivables 153,367
Other Current Assets 35,700
Total Current Assets  (as reported)742,145
Total Current Assets  (calculated)742,145
+/-0
Long-term Assets
Property Plant Equipment 424,020
Goodwill 47,806
Long Term Investments 90,374
Intangible Assets 40,262
Long-term Assets Other 57,454
Long-term Assets  (as reported)659,916
Long-term Assets  (calculated)659,916
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities67,023
Long-term Liabilities327,962
Total Stockholder Equity1,007,076
Total Current Liabilities
Short-term Debt 9,792
Accounts payable 32,041
Other Current Liabilities 69
Total Current Liabilities  (as reported)67,023
Total Current Liabilities  (calculated)41,902
+/- 25,121
Long-term Liabilities
Capital Lease Obligations 142,080
Long-term Liabilities Other 1,560
Long-term Liabilities  (as reported)327,962
Long-term Liabilities  (calculated)143,640
+/- 184,322
Total Stockholder Equity
Common Stock791,668
Retained Earnings 36,582
Accumulated Other Comprehensive Income -2,657
Other Stockholders Equity 181,483
Total Stockholder Equity (as reported)1,007,076
Total Stockholder Equity (calculated)1,007,076
+/-0
Other
Capital Stock791,668
Cash and Short Term Investments 553,078
Common Stock Shares Outstanding 298,509
Current Deferred Revenue25,121
Liabilities and Stockholders Equity 1,402,061
Net Debt 49,643
Net Invested Capital 1,007,076
Net Working Capital 675,122
Property Plant and Equipment Gross 472,534
Short Long Term Debt Total 142,080



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
23,488
0
155,216
142,385
1,005,536
1,128,523
1,151,856
1,172,732
1,318,569
1,592,289
1,593,784
1,552,409
1,540,907
1,497,919
1,537,166
1,512,190
1,488,094
1,463,096
1,412,481
1,392,828
1,360,553
1,344,208
1,402,061
1,402,0611,344,2081,360,5531,392,8281,412,4811,463,0961,488,0941,512,1901,537,1661,497,9191,540,9071,552,4091,593,7841,592,2891,318,5691,172,7321,151,8561,128,5231,005,536142,385155,216023,488000
   > Total Current Assets 
10,444
0
0
12,640
7,553
128,701
114,000
813,325
907,982
864,002
803,747
929,800
1,174,378
1,143,955
1,045,669
1,025,491
940,653
930,735
919,518
871,985
813,948
771,554
742,883
751,370
764,978
742,145
742,145764,978751,370742,883771,554813,948871,985919,518930,735940,6531,025,4911,045,6691,143,9551,174,378929,800803,747864,002907,982813,325114,000128,7017,55312,6400010,444
       Cash And Cash Equivalents 
-10,444
0
0
7,553
-7,553
113,137
91,082
594,116
685,795
792,571
517,694
476,142
545,718
790,615
371,973
386,535
193,017
179,747
172,422
133,320
123,572
148,312
126,640
156,325
159,266
92,437
92,437159,266156,325126,640148,312123,572133,320172,422179,747193,017386,535371,973790,615545,718476,142517,694792,571685,795594,11691,082113,137-7,5537,55300-10,444
       Short-term Investments 
20,889
0
0
594,116
15,106
19,247
594,116
0
32,187
42,705
235,785
246,835
240,335
231,652
496,233
499,950
603,478
615,947
613,418
627,265
574,451
522,044
516,499
469,289
446,000
460,641
460,641446,000469,289516,499522,044574,451627,265613,418615,947603,478499,950496,233231,652240,335246,835235,78542,70532,1870594,11619,24715,106594,1160020,889
       Net Receivables 
0
0
0
4,377
14,522
292
20,109
213,239
216,691
65,306
43,633
160,576
334,403
52,797
105,964
103,410
99,569
86,233
75,483
64,382
68,775
67,703
63,236
92,130
126,614
153,367
153,367126,61492,13063,23667,70368,77564,38275,48386,23399,569103,410105,96452,797334,403160,57643,63365,306216,691213,23920,10929214,5224,377000
       Other Current Assets 
0
0
0
547
0
15,271
1,781
4,562
4,287
4,916
5,303
44,575
28,922
43,891
46,499
34,064
43,142
47,361
57,001
45,911
46,412
33,495
36,508
33,626
33,098
35,700
35,70033,09833,62636,50833,49546,41245,91157,00147,36143,14234,06446,49943,89128,92244,5755,3034,9164,2874,5621,78115,2710547000
   > Long-term Assets 
-10,444
0
0
10,848
-7,553
26,515
28,386
192,211
220,541
287,854
368,985
388,769
417,911
449,829
506,740
515,416
557,266
606,431
592,672
616,109
649,148
640,927
649,945
609,183
579,230
659,916
659,916579,230609,183649,945640,927649,148616,109592,672606,431557,266515,416506,740449,829417,911388,769368,985287,854220,541192,21128,38626,515-7,55310,84800-10,444
       Property Plant Equipment 
0
0
0
8,480
11,616
11,616
14,278
17,923
34,618
87,479
91,584
111,616
122,049
149,178
200,602
217,255
233,187
259,640
277,209
287,696
306,081
318,882
331,263
340,429
347,102
424,020
424,020347,102340,429331,263318,882306,081287,696277,209259,640233,187217,255200,602149,178122,049111,61691,58487,47934,61817,92314,27811,61611,6168,480000
       Goodwill 
0
0
0
31,500
0
31,500
31,500
31,500
31,500
31,500
49,457
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,80647,80647,80647,80647,80647,80647,80647,80647,80647,80647,80647,80647,80647,80647,80649,45731,50031,50031,50031,50031,500031,500000
       Long Term Investments 
0
0
0
0
0
0
0
19,247
32,187
42,705
47,507
50,313
58,882
65,824
66,718
72,522
57,583
58,792
62,887
65,938
71,592
76,064
84,084
82,297
81,567
90,374
90,37481,56782,29784,08476,06471,59265,93862,88758,79257,58372,52266,71865,82458,88250,31347,50742,70532,18719,2470000000
       Intangible Assets 
0
0
0
115,153
0
13,574
13,253
115,153
112,688
110,223
148,821
148,392
145,785
143,179
142,548
131,502
128,845
126,747
124,076
120,425
118,736
85,661
52,577
42,113
41,192
40,262
40,26241,19242,11352,57785,661118,736120,425124,076126,747128,845131,502142,548143,179145,785148,392148,821110,223112,688115,15313,25313,5740115,153000
       Long-term Assets Other 
-10,444
0
0
585
-7,553
1,324
-132,110
2,490
9,548
15,947
31,616
23,234
43,389
43,842
49,066
46,331
89,845
113,446
80,694
94,244
54,433
57,814
134,215
96,538
61,563
57,454
57,45461,56396,538134,21557,81454,43394,24480,694113,44689,84546,33149,06643,84243,38923,23431,61615,9479,5482,490-132,1101,324-7,55358500-10,444
> Total Liabilities 
0
0
0
13,236
0
64,323
53,147
175,028
171,399
184,177
219,335
292,836
384,782
380,928
302,237
307,630
289,419
342,339
329,415
335,776
333,183
301,513
314,734
304,469
321,226
394,985
394,985321,226304,469314,734301,513333,183335,776329,415342,339289,419307,630302,237380,928384,782292,836219,335184,177171,399175,02853,14764,323013,236000
   > Total Current Liabilities 
0
0
0
7,895
18,269
18,269
20,104
103,490
88,395
69,758
49,549
120,676
213,418
221,140
106,052
118,320
89,591
118,905
110,239
119,013
104,883
70,380
79,568
76,612
75,396
67,023
67,02375,39676,61279,56870,380104,883119,013110,239118,90589,591118,320106,052221,140213,418120,67649,54969,75888,395103,49020,10418,26918,2697,895000
       Short-term Debt 
0
0
0
2,886
0
799
320
865
1,533
2,220
2,800
3,652
3,920
4,023
4,517
5,583
5,868
5,953
5,572
6,158
5,531
5,603
10,250
9,242
9,274
9,792
9,7929,2749,24210,2505,6035,5316,1585,5725,9535,8685,5834,5174,0233,9203,6522,8002,2201,53386532079902,886000
       Short Long Term Debt 
0
0
0
2,467
0
0
320
190
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000190320002,467000
       Accounts payable 
0
0
0
1,644
2,522
2,522
2,986
7,320
3,585
5,605
8,908
14,924
10,352
10,313
9,319
14,828
17,569
21,025
17,432
28,603
26,907
26,585
34,795
34,350
32,804
32,041
32,04132,80434,35034,79526,58526,90728,60317,43221,02517,56914,8289,31910,31310,35214,9248,9085,6053,5857,3202,9862,5222,5221,644000
       Other Current Liabilities 
0
0
0
-36,055
14,948
-29,279
-26,271
52,564
41,941
45,543
21,134
58,881
79,258
89,089
56,098
70,012
47,762
61,827
63,374
58,182
61,880
31,791
28,945
11,841
7,321
69
697,32111,84128,94531,79161,88058,18263,37461,82747,76270,01256,09889,08979,25858,88121,13445,54341,94152,564-26,271-29,27914,948-36,055000
   > Long-term Liabilities 
0
0
0
5,341
0
46,054
33,043
71,538
83,004
114,419
169,786
172,160
171,364
159,788
196,185
189,310
199,828
223,434
219,176
216,763
228,300
231,133
235,166
227,857
245,830
327,962
327,962245,830227,857235,166231,133228,300216,763219,176223,434199,828189,310196,185159,788171,364172,160169,786114,41983,00471,53833,04346,05405,341000
       Other Liabilities 
0
0
0
1,336
26,686
26,686
28,038
65,625
65,131
83,399
142,522
134,014
135,008
127,029
124,594
112,635
0
145,355
143,991
0
0
0
0
0
0
0
0000000143,991145,3550112,635124,594127,029135,008134,014142,52283,39965,13165,62528,03826,68626,6861,336000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
26,992
25,510
36,197
37,370
36,804
34,616
34,143
33,178
33,426
33,178
0
0
0
0
0
0
0
0
0000000033,17833,42633,17834,14334,61636,80437,37036,19725,51026,99200000000
> Total Stockholder Equity
11,609
0
0
10,252
10,252
90,892
89,238
830,508
957,124
967,679
953,397
1,025,733
1,207,507
1,212,856
1,250,172
1,233,277
1,208,500
1,194,827
1,182,775
1,152,318
1,129,913
1,110,968
1,078,094
1,056,084
1,022,982
1,007,076
1,007,0761,022,9821,056,0841,078,0941,110,9681,129,9131,152,3181,182,7751,194,8271,208,5001,233,2771,250,1721,212,8561,207,5071,025,733953,397967,679957,124830,50889,23890,89210,25210,2520011,609
   Common Stock
0
0
0
5,122
5,373
5,373
88,582
710,387
711,139
714,758
718,088
722,430
725,755
726,825
730,427
734,365
742,816
744,756
747,914
753,199
764,562
769,966
772,832
777,171
790,068
791,668
791,668790,068777,171772,832769,966764,562753,199747,914744,756742,816734,365730,427726,825725,755722,430718,088714,758711,139710,38788,5825,3735,3735,122000
   Retained Earnings Total Equity
0
0
0
0
0
0
0
0
231,423
229,100
207,720
267,666
436,239
429,454
456,078
426,185
386,075
355,547
0
0
0
0
0
0
0
0
00000000355,547386,075426,185456,078429,454436,239267,666207,720229,100231,42300000000
   Accumulated Other Comprehensive Income 
4,052
0
0
-3,157
2,706
0
0
0
0
2,152
644
280
787
576
-717
-1,391
-2,021
-1,899
-1,460
-1,720
-1,816
-2,073
-1,232
-4,378
-6,998
-2,657
-2,657-6,998-4,378-1,232-2,073-1,816-1,720-1,460-1,899-2,021-1,391-7175767872806442,15200002,706-3,157004,052
   Capital Surplus 
0
0
0
0
0
0
0
0
14,562
21,669
26,945
35,357
44,726
56,001
64,384
74,118
81,630
96,423
0
0
0
0
0
0
0
0
0000000096,42381,63074,11864,38456,00144,72635,35726,94521,66914,56200000000
   Treasury Stock00000000000000000000000000
   Other Stockholders Equity 
0
0
0
5,457
0
3,397
-78,755
5,919
14,562
21,669
26,945
35,357
44,726
56,001
64,384
74,118
81,630
96,423
109,384
121,052
127,990
140,828
155,354
166,361
168,603
181,483
181,483168,603166,361155,354140,828127,990121,052109,38496,42381,63074,11864,38456,00144,72635,35726,94521,66914,5625,919-78,7553,39705,457000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue28,833
Cost of Revenue-96,999
Gross Profit-68,166-68,166
 
Operating Income (+$)
Gross Profit-68,166
Operating Expense-246,600
Operating Income-314,766-314,766
 
Operating Expense (+$)
Research Development167,259
Selling General Administrative72,711
Selling And Marketing Expenses12,779
Operating Expense246,600252,749
 
Net Interest Income (+$)
Interest Income38,473
Interest Expense-0
Other Finance Cost-0
Net Interest Income38,473
 
Pretax Income (+$)
Operating Income-314,766
Net Interest Income38,473
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-200,395-429,137
EBIT - interestExpense = -301,147
-200,395
-162,857
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-301,147-200,395
Earnings Before Interest and Taxes (EBITDA)-204,148
 
After tax Income (+$)
Income Before Tax-200,395
Tax Provision--37,538
Net Income From Continuing Ops-162,857-162,857
Net Income-162,857
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses343,599
Total Other Income/Expenses Net114,371-38,473
 

Technical Analysis of Abcellera
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Abcellera. The general trend of Abcellera is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Abcellera's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Abcellera Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Abcellera Biologics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 4.81 < 5.01 < 5.26.

The bearish price targets are: 3.93 > 3.87 > 3.83.

Know someone who trades $ABCL? Share this with them.👇

Abcellera Biologics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Abcellera Biologics Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Abcellera Biologics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Abcellera Biologics Inc. The current macd is 0.05386691.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Abcellera price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Abcellera. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Abcellera price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Abcellera Biologics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAbcellera Biologics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Abcellera Biologics Inc. The current adx is 22.70.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Abcellera shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Abcellera Biologics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Abcellera Biologics Inc. The current sar is 3.91405168.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Abcellera Biologics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Abcellera Biologics Inc. The current rsi is 61.05. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Abcellera Biologics Inc Daily Relative Strength Index (RSI) ChartAbcellera Biologics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Abcellera Biologics Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Abcellera price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Abcellera Biologics Inc Daily Stochastic Oscillator ChartAbcellera Biologics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Abcellera Biologics Inc. The current cci is 176.21.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Abcellera Biologics Inc Daily Commodity Channel Index (CCI) ChartAbcellera Biologics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Abcellera Biologics Inc. The current cmo is 31.78.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Abcellera Biologics Inc Daily Chande Momentum Oscillator (CMO) ChartAbcellera Biologics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Abcellera Biologics Inc. The current willr is -7.84313725.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Abcellera Biologics Inc Daily Williams %R ChartAbcellera Biologics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Abcellera Biologics Inc.

Abcellera Biologics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Abcellera Biologics Inc. The current atr is 0.30467116.

Abcellera Biologics Inc Daily Average True Range (ATR) ChartAbcellera Biologics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Abcellera Biologics Inc. The current obv is 62,219,458.

Abcellera Biologics Inc Daily On-Balance Volume (OBV) ChartAbcellera Biologics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Abcellera Biologics Inc. The current mfi is 50.29.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Abcellera Biologics Inc Daily Money Flow Index (MFI) ChartAbcellera Biologics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Abcellera Biologics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-09STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-10ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-16STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-09-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Abcellera Biologics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Abcellera Biologics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.046
Ma 20Greater thanMa 504.295
Ma 50Greater thanMa 1004.388
Ma 100Greater thanMa 2003.525
OpenGreater thanClose4.360
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Abcellera with someone you think should read this too:
  • Are you bullish or bearish on Abcellera? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Abcellera? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Abcellera Biologics Inc

I send you an email if I find something interesting about Abcellera Biologics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Abcellera Biologics Inc.

Receive notifications about Abcellera Biologics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.